Faculty of Nursing, University of Cantabria, Avda Valdecilla s/n. C.P., 39008 Santander, Cantabria, Spain.
Breastfeeding Coordinator, IBCLC, Hospital Universitario Marqués de Valdecilla, C.P., 39008 Santander, Cantabria, Spain.
Int J Environ Res Public Health. 2021 Aug 21;18(16):8831. doi: 10.3390/ijerph18168831.
Breastfeeding mothers were excluded from the clinical trials conducted for vaccines against SARS-CoV-2. Since the start of the vaccination, some doubts have arisen regarding its compatibility with breastfeeding. The aim of this study was to analyse the presence of anti-SARS-CoV-2 antibodies in breast milk and serum (IgG and IgA) of vaccinated breastfeeding women. The main variables of the observational study were: adverse related events after vaccination and determination of the presence of IgG and IgA isotypes antibodies in serum and in breast milk of vaccinated women against the SARS-CoV-2 antigens. Results: 110 breastfeeding mothers were included; 70 women (63.6%) were vaccinated with two doses of BNT162b2, 20 women (18.2%) with two doses of mRNA-1273, and 20 women (18.2%) with a single dose of ChAdOx1-S. Regarding adverse reactions and vaccine safety, 38 women had no adverse reactions; 20 (18.2%) had general malaise or adenopathies; 10 (9.1%) had a headache; and 7 (6.4%) had fever. When analysing IgG antibodies, significantly higher levels of antibodies were found in serum and breast milk from mothers vaccinated with BNT162b2 or mRNA-1273 vs. ChAdOx1-S ( < 0.001 and = 0.001, respectively). Analysing IgA antibodies, significant differences were found when comparing mean values in serum from mothers vaccinated with BNT162b2 or mRNA-1273 vs. ChAdOx1-S (0.12, 0.16, and 0.02, respectively; < 0.001) and breast milk of mothers vaccinated when comparing BNT16b2 vs. ChAdOx1-S. All vaccinated breastfeeding mothers had serum anti-S1 IgG antibodies in response to vaccination against SARS-CoV-2, regardless of the commercial vaccine administered. Conclusions: the anti-SARS-CoV-2 vaccines were well tolerated by the mothers and the breastfed infant. In addition, breastfeeding mothers offer their infants IgA and IgG isotype antibodies directed against SARS-CoV-2 protein S in breast milk.
母乳喂养的母亲被排除在针对 SARS-CoV-2 的疫苗临床试验之外。自疫苗接种开始以来,人们对其与母乳喂养的兼容性产生了一些疑问。本研究旨在分析接种疫苗的母乳喂养妇女的母乳和血清(IgG 和 IgA)中是否存在抗 SARS-CoV-2 抗体。这项观察性研究的主要变量是:接种疫苗后的不良相关事件以及确定接种 SARS-CoV-2 抗原的妇女的血清和母乳中 IgG 和 IgA 同种型抗体的存在。结果:纳入 110 名母乳喂养的母亲;70 名女性(63.6%)接种了两剂 BNT162b2,20 名女性(18.2%)接种了两剂 mRNA-1273,20 名女性(18.2%)接种了一剂 ChAdOx1-S。关于不良反应和疫苗安全性,38 名女性没有不良反应;20 名(18.2%)有全身不适或腺病;10 名(9.1%)有头痛;7 名(6.4%)有发热。分析 IgG 抗体时,发现接种 BNT162b2 或 mRNA-1273 的母亲的血清和母乳中的抗体水平明显高于接种 ChAdOx1-S 的母亲(<0.001 和=0.001)。分析 IgA 抗体时,发现接种 BNT162b2 或 mRNA-1273 的母亲的血清中的平均值存在显著差异与 ChAdOx1-S(0.12、0.16 和 0.02,分别;<0.001),而接种 BNT16b2 的母亲的母乳中的平均值与 ChAdOx1-S 存在显著差异。所有接种疫苗的母乳喂养母亲对 SARS-CoV-2 的疫苗接种均产生了血清抗 S1 IgG 抗体,无论接种的商业疫苗如何。结论:抗 SARS-CoV-2 疫苗被母亲和母乳喂养的婴儿很好地耐受。此外,母乳喂养的母亲在母乳中为婴儿提供针对 SARS-CoV-2 蛋白 S 的 IgA 和 IgG 同种型抗体。